Development and Validation of an Artificial Intelligence‐Driven Multigene Assay Decision‐Support System for Personalized Management of T1 High‐Grade Bladder Cancer

T1 high‐grade bladder cancer presents a therapeutic dilemma, as current risk stratification fails to guide the choice between early cystectomy and bladder‐preserving therapy. In our recent work, we defined a high‐risk multiomic subtype driven by anoikis resistance and immune evasion and developed the T1HG‐UCBguider framework for risk stratification; however, its reliance on multiomic sequencing limits clinical implementation. Here, we translate this framework into Guider, an artificial intelligence‐driven reverse transcription‐quantitative polymerase chain reaction (RT‐qPCR) decision‐aid designed for cost‐conscious use in routine pathology workflows and integrating a 30‐gene TaqMan assay with clinicopathological variables to predict progression and recurrence, with exploratory treatment‐context modules for no instillation, Bacillus Calmette–Guérin, and intravesical chemotherapy. In a multicenter ambispective cohort of 1198 patients, Guider achieved > 10% higher absolute predictive performance than guideline‐based risk groups and the published 12‐gene progression score within this Chinese T1 high‐grade cohort. Reclassification identified 82.5% of guideline‐defined high‐risk patients who progressed and 45.1% of very‐high‐risk nonprogressors who might be considered for bladder preservation. Guider could potentially support treatment de‐escalation in 29.7% and escalation in 12.9% of patients. These findings establish a scalable translational framework bridging multiomic discovery and clinical decision support, warranting prospective interventional validation in geographically, ethnically, and demographically diverse populations.

Authors

Institutions

Publication Details

Journal
MedComm
Published
2026-11-20
DOI
https://doi.org/10.1002/mco2.71155
Primary Topic
Bladder and Urothelial Cancer Treatments
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Development and Validation of an Artificial Intelligence‐Driven Multigene Assay Decision‐Support System for Personalized Management of T1 High‐Grade Bladder Cancer

Shufan Fu, Weimin Ci, 唐锦禄, Shengwei Xiong et al.
MedComm
Bladder and Urothelial Cancer Treatments
article

Development and Validation of an Artificial Intelligence‐Driven Multigene Assay Decision‐Support System for Personalized Management of T1 High‐Grade Bladder Cancer

Shufan Fu, Weimin Ci, 唐锦禄, Shengwei Xiong, 许春茹, Qingming Shu, Yue Shi, Bingyang Guo, Aitao Guo, Zexuan Lv, Qiang Cheng, Xu Zhang, Yi Feng, Yuan Liang, Yihe Zhao, Ying Wang, Hongzhao Li, Xuesong Li, Yang Yang, Bin Guo, Guodong Li, Gaojie Li
article en

Abstract

T1 high‐grade bladder cancer presents a therapeutic dilemma, as current risk stratification fails to guide the choice between early cystectomy and bladder‐preserving therapy. In our recent work, we defined a high‐risk multiomic subtype driven by anoikis resistance and immune evasion and developed the T1HG‐UCBguider framework for risk stratification; however, its reliance on multiomic sequencing limits clinical implementation. Here, we translate this framework into Guider, an artificial intelligence‐driven reverse transcription‐quantitative polymerase chain reaction (RT‐qPCR) decision‐aid designed for cost‐conscious use in routine pathology workflows and integrating a 30‐gene TaqMan assay with clinicopathological variables to predict progression and recurrence, with exploratory treatment‐context modules for no instillation, Bacillus Calmette–Guérin, and intravesical chemotherapy. In a multicenter ambispective cohort of 1198 patients, Guider achieved > 10% higher absolute predictive performance than guideline‐based risk groups and the published 12‐gene progression score within this Chinese T1 high‐grade cohort. Reclassification identified 82.5% of guideline‐defined high‐risk patients who progressed and 45.1% of very‐high‐risk nonprogressors who might be considered for bladder preservation. Guider could potentially support treatment de‐escalation in 29.7% and escalation in 12.9% of patients. These findings establish a scalable translational framework bridging multiomic discovery and clinical decision support, warranting prospective interventional validation in geographically, ethnically, and demographically diverse populations.

MedCommVol. 7(12)
Chinese PLA General Hospital (CN), Central China Normal University (CN), Gannan Medical University (CN), Peking University First Hospital (CN)
Bladder and Urothelial Cancer Treatments
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon